Pharmacokinetics and metabolism studies on the glucagon-like peptide-1 (GLP-1)-derived metabolite GLP-1(9-36)amide in male Beagle dogs

Xenobiotica

Volumn 44, Issue 9, 2014, Pages 842-848

  Eng, Heather ^a   Sharma, Raman ^a   McDonald, Thomas S ^a   Landis, Margaret S ^a   Stevens, Benjamin D ^a,b   Kalgutkar, Amit S ^a  

^a PFIZER INC   (United States)

^b Wolf   (United States)

Author keywords

Amidase; Cardiovascular; Dog; Glucagon like peptide; Hepatocytes; Metabolite; Pharmacokinetics

Indexed keywords

BOVINE SERUM ALBUMIN; GLUCAGON LIKE PEPTIDE 1; PEPTIDE; CARDIOTONIC AGENT; GLUCAGON-LIKE PEPTIDE-1 (9-36)-AMIDE; INSULIN;

AMINO TERMINAL SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BEAGLE; DISTRIBUTION VOLUME; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG STABILITY; ENZYME LINKED IMMUNOSORBENT ASSAY; HEART FAILURE; HEART PROTECTION; HUMAN; HUMAN CELL; IN VITRO STUDY; LIQUID CHROMATOGRAPHY; LIVER CELL; MALE; MAXIMUM PLASMA CONCENTRATION; METABOLISM; METABOLITE; NONHUMAN; PLASMA; PLASMA CLEARANCE; PROTEIN DEGRADATION; STEADY STATE; TANDEM MASS SPECTROMETRY; VASODILATATION; ANALOGS AND DERIVATIVES; ANIMAL; BLOOD; DOG; DRUG EFFECTS; MOUSE; SECRETION (PROCESS);

ANIMALS; CARDIOTONIC AGENTS; CHROMATOGRAPHY, LIQUID; DOGS; GLUCAGON-LIKE PEPTIDE 1; HEPATOCYTES; HUMANS; INSULIN; MALE; MICE; PEPTIDES; TANDEM MASS SPECTROMETRY;

EID: 84905401781     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.3109/00498254.2014.897011     Document Type: Article

References (30)

1. Abu-Hamdah R, Rabiee A, Meneilly GS, et al. (2009). Clinical review: the extrapancreatic effects of glucagon-like peptide-1 and related peptides. J Clin Endocrinol Metab 94:1843-52.
2. Angeli FS, Shannon RP. (2013). Incretin based therapies: can we achieve glycemic control and cardioprotection? J Endocrinol In Press.
3. Ban K, Hui S, Drucker DJ, Husain M. (2009). Cardiovascular consequences of drugs used in the treatment of diabetes: potential promise of incretin-based therapies. J Am Soc Hypertens 3:245-59.
4. Ban K, Noyan-Ashraf MH, Hoefer J, et al. (2008). Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor-dependent and independent pathways. Circulation 117:2340-50.
5. Bhashyam S, Fields AV, Patterson B, et al. (2010). Glucagon-like peptide-1 increases myocardial glucose uptake via p38alpha MAP kinase-mediated, nitric oxide dependent mechanisms in conscious dogs with dilated cardiomyopathy. Circ Heart Fail 3:512-21.
6. Cernea S, Raz I. (2011). Therapy in the early stage: incretins. Diabetes Care 34(Suppl 2):S264-71.
7. Chappell DL, Lee AY, Castro-Perez J, et al. (2014). An ultrasensitive method for the quantitation of active and inactive GLP-1 in human plasma via immunoaffinity LC-MS/MS. Bioanalysis 6:33-42.
8. Davis B, Morris T. (1993). Physiological parameters in laboratory animals and humans. Pharm Res 10:1093-5.
9. Deacon CF, Johnsen AH, Holst JJ. (1995a). Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. J Clin Endocr Metab 80:952-7.
10. 2-terminus in type II diabetic patients and in healthy subjects. Diabetes 44:1126-31.
11. Edwards C. (2013). Glucagon-like peptide-1 agonists in the treatment of type 2 diabetes. Br J Hosp Med (Lond) 74:198-201.
12. Elahi D, Egan JM, Shannon RP, et al. (2008). Glucagon-like peptide-1 (9-36) amide, cleavage product of glucagon-like peptide-1 (7-36) is a glucoregulatory peptide. Obesity 16:1501-9.
13. Fineman MS, Cirincione BB, Maggs D, Diamant M. (2012). GLP-1 based therapies: differential effects on fasting and postprandial glucose. Diabetes Obes Metab 14:675-88.
14. Hansen L, Deacon CF, Orskov C, Holst JJ. (1999). Glucagon-like peptide-1-(7-36)amide is transformed to glucagon-like peptide-1-(9-36)amide by dipeptidyl peptidase IV in the capillaries supplying the L cells of the porcine intestine. Endocrinology 140:5356-63.
15. Holst JJ. (2007). The physiology of glucagon-like peptide 1. Physiol Rev 87:1409-39.
16. Houston JB. (1994). Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance. Biochem Pharmacol 47:1469-79.
17. Hupe-Sodmann K, McGregor GP, Bridenbaugh R, et al. (1995). Characterization of the processing by human neutral endopeptidase 24.11 of GLP-1(7-36) amide and comparison of the substrate specificity of the enzyme for other glucagon-like peptides. Regul Pept 58:149-56.
18. Medzihradszky KF. (2005). Peptide sequence analysis. Methods Enzymol 402:209-44.
19. Mentlein R. (1999). Dipeptidyl-peptidase IV (CD26)-role in the inactivation of regulatory peptides. Regul Pept 85:9-24.
20. Mundil D, Cameron-Vendrig A, Husain M. (2012). GLP-1 receptor agonists: a clinical perspective on cardiovascular effects. Diab Vasc Dis Res 9:95-108.
21. Nikolaidis LA, Elahi D, Hentosz T, et al. (2004). Recombinant glucagon-like peptide-1 increases myocardial glucose uptake and improves left ventricular performance in conscious dogs with pacing-induced dilated cardiomyopathy. Circulation 110:955-61.
22. Nikolaidis LA, Elahi D, Shen YT, Shannon RP. (2005). Active metabolite of GLP-1 mediates myocardial glucose uptake and improves left ventricular performance in conscious dogs with dilated cardiomyopathy. Am J Physiol Heart Circ Physiol 289: H2401-8.
23. Obach RS, Baxter JG, Liston TE, et al. (1997). The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data. J Pharmacol Exp Ther 283:46-58.
24. Pridal L, Deacon CF, Kirk O, et al. (1996). Glucagon-like peptide peptide-1(7-37) has a larger volume of distribution than glucagon-like peptide-1(7-36)amide in dogs and is degraded more quickly in vitro by dog plasma. Eur J Drug Metab Pharmacokinet 21:51-9.
25. Sharma R, McDonald TS, Eng H, et al. (2013). In vitro metabolism of the glucagon-like peptide-1 (GLP-1)-derived metabolites GLP-1(9-36)amide and GLP-1(28-36)amide in mouse and human hepatocytes. Drug Metab Dispos 41:2148-57.
26. Thorens B. (1992). Expression cloning of the pancreatic beta cell receptor for the gluco-incretin hormone glucagon-like peptide 1. Proc Natl Acad Sci USA 89:8641-5.
27. Tomas E, Habener JF. (2010). Insulin-like actions of glucagon-like peptide-1: a dual receptor hypothesis. Trends Endocrinol Metab 21: 59-67.
28. Tomas E, Stanojevic V, Habener JF. (2010). GLP-1 (9-36) amide metabolite suppression of glucose production in isolated mouse hepatocytes. Horm Metab Res 42:657-62.
29. Ussher JR, Drucker DJ. (2012). Cardiovascular biology of the incretin system. Endocr Rev 33:187-215.
30. Wysocki VH, Resing KA, Zhang Q, Cheng G. (2005). Mass spectrom-etry of peptides and proteins. Methods 35:211-22.